thrombolysis in myocardial infarction


Also found in: Acronyms, Wikipedia.

thrombolysis in myocardial infarction

,

TIMI

A large series of studies on the use of thrombolytic drugs and percutaneous coronary intervention in patients with acute coronary syndromes. The studies are sponsored by the Thrombolysis in Myocardial Infarction Study Group (TIMI Study Group). Website: www.timi.org
References in periodicals archive ?
The thrombolysis in myocardial infarction risk score in unstable angina/non-ST-segment elevation myocardial infarction.
A Thrombolysis In Myocardial Infarction score >4 and Global Registry of Acute Coronary Events score >133 was significantly associated with 3vessel disease and left main disease, while for the former score <4 and latter score <133 was associated with normal or non-obstructive coronary disease (p<0.
Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase.
Thrombolysis in myocardial infarction (TIMI) trial and TIMI myocardial perfusion grade (TMPG) of infarction-related blood vessels after PCI were recorded.
Objective: In this study, it was aimed to investigate the effect of streptokinase therapy in ST elevation myocardial infarction (STEMI) and conventional therapy in non-ST elevation myocardial infarction (NSTEMI) patients on the thrombolysis in myocardial infarction (TIMI) risk index (TRI), B-type natriuretic peptide (BNP), and high-sensitive C-reactive protein (hs-CRP)levels.
Myoglobin, creatine-kinase-MB and cardiac troponin-I 60-minute ratios predict infarct-related artery patency after thrombolysis for acute myocardial infarction: results from the Thrombolysis in Myocardial Infarction study (TIMI) 1013.
Following earlier completion of Phase I studies, manufacturing capability was established during the year and BB-10153 has recently started a Phase II trial in heart attack patients under the auspices of the Thrombolysis in Myocardial Infarction Group in the USA.
He analyzed the records of 20,101 acute MI patients who participated in the Thrombolysis in Myocardial Infarction (TIMI) 4, 9A, 9B, and l0B trials and in the Intravenous NPA [lanoteplase] for Treatment of Infarcting Myocardium Early-II (In TIME-II) trial.
In accordance with convention, patency in the infarct-related artery is graded by angiography according to the Thrombolysis in Myocardial Infarction (TIMI) criteria, in which TIMI 0 is no perfusion past the occlusion; TIMI 1 is penetration past the occlusion without perfusion; TIMI 2 is partial perfusion past the occlusion; and TIMI 3 is complete perfusion (63).